TY - JOUR T1 - Systematic single-variant and gene-based association testing of 3,700 phenotypes in 281,850 UK Biobank exomes JF - medRxiv DO - 10.1101/2021.06.19.21259117 SP - 2021.06.19.21259117 AU - Konrad J. Karczewski AU - Matthew Solomonson AU - Katherine R. Chao AU - Julia K. Goodrich AU - Grace Tiao AU - Wenhan Lu AU - Bridget M. Riley-Gillis AU - Ellen A. Tsai AU - Hye In Kim AU - Xiuwen Zheng AU - Fedik Rahimov AU - Sahar Esmaeeli AU - A. Jason Grundstad AU - Mark Reppell AU - Jeff Waring AU - Howard Jacob AU - David Sexton AU - Paola G. Bronson AU - Xing Chen AU - Xinli Hu AU - Jacqueline I. Goldstein AU - Daniel King AU - Christopher Vittal AU - Timothy Poterba AU - Duncan S. Palmer AU - Claire Churchhouse AU - Daniel P. Howrigan AU - Wei Zhou AU - Nicholas A. Watts AU - Kevin Nguyen AU - Huy Nguyen AU - Cara Mason AU - Christopher Farnham AU - Charlotte Tolonen AU - Laura D. Gauthier AU - Namrata Gupta AU - Daniel G. MacArthur AU - Heidi L. Rehm AU - Cotton Seed AU - Anthony A. Philippakis AU - Mark J. Daly AU - J. Wade Davis AU - Heiko Runz AU - Melissa R. Miller AU - Benjamin M. Neale Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/23/2021.06.19.21259117.abstract N2 - Genome-wide association studies have successfully discovered thousands of common variants associated with human diseases and traits, but the landscape of rare variation in human disease has not been explored at scale. Exome sequencing studies of population biobanks provide an opportunity to systematically evaluate the impact of rare coding variation across a wide range of phenotypes to discover genes and allelic series relevant to human health and disease. Here, we present results from systematic association analyses of 3,700 phenotypes using single-variant and gene tests of 281,850 individuals in the UK Biobank with exome sequence data. We find that the discovery of genetic associations is tightly linked to frequency as well as correlated with metrics of deleteriousness and natural selection. We highlight biological findings elucidated by these data and release the dataset as a public resource alongside a browser framework for rapidly exploring rare variant association results.Competing Interest StatementKJK is a consultant for Vor Biopharma. BRG, XZ, FR, SE, AJG, MR, JW, HJ, JWD are employees of AbbVie Inc. MR is an employee of and owns stock in AbbVie Inc. EAT, DS, PGB, HR are employees of Biogen and hold stocks/stock options in Biogen. HK, XC, XH and MRM are employees of Pfizer. DK holds stock in the private company TriNetX, LLC. DSP was an employee of Genomics plc. All the analyses reported in this paper were performed as part of DSP's previous employment at the Massachusetts General Hospital and Broad Institute. NAW owns stock in Pfizer. LDG receives funding from Intel and Illumina. DGM is a founder with equity of Goldfinch Bio, and serves as a paid advisor to GSK, Variant Bio, Insitro, and Foresite Labs. HLR is a member of the scientific advisory board at Genome Medical. AAP is a Venture Partner at GV. He has received consulting fees from Novartis, and receives funding from Bayer, IBM, Microsoft, Alphabet, Intel, GSK, Pfizer, Illumina. MJD is a founder of Maze Therapeutics. BMN is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics, member of the scientific advisory committee at Milken and a consultant for Camp4 Therapeutics, Merck and Biogen.Funding StatementThis work was funded by Abbvie, Biogen, and Pfizer, who are represented by co-authors on this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank applications 26041 and 48511All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available at https://genebass.org ER -